Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- Drug: placebo nasal spray
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 201
- Registration Number
- NCT03861559
Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic
- Interventions
- Drug: Placebo tabletDrug: Placebo nasal spray
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 704
- Registration Number
- NCT03855228
Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 345
- Registration Number
- NCT03855189
Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Combination Product: EZ 10 mg/Ator 10 mgCombination Product: EZ 10 mg/Ator 20 mgDrug: Placebo for FDC EZ/Ator
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 454
- Registration Number
- NCT03768427
- Locations
- 🇨🇳
The First Affiliated Hospital of Baotou Medical College ( Site 0025), Baotou, Anhui, China
🇨🇳Beijing Anzhen Hospital. Capital Medical University ( Site 0001), Beijing, Anhui, China
🇨🇳Aero Space center hospital ( Site 0003), Beijing, Beijing, China
Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
Phase 3
Completed
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 17
- Registration Number
- NCT03019575
- Locations
- 🇧🇷
Centro de Diabetes Curitiba ( Site 0012), Curitiba, Brazil
🇧🇷Hospital de Clinicas de Porto Alegre ( Site 0014), Porto Alegre, Brazil
🇧🇷Hosp das Clinicas da Faculdade de Medicina da Univ de Sao Paulo ( Site 0015), Sao Paulo, Brazil
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
Phase 3
Completed
- Conditions
- Familial HypercholesterolemiaHypercholesterolemia
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 135
- Registration Number
- NCT02748057
Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: MF MDI 100 mcg BID (Open Label)Drug: MF/F MDI 100/10 mcg BIDDrug: MF MDI 100 mcg BIDDrug: Albuterol/Salbutamol PRNDrug: Prednisone/Prednisolone
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 181
- Registration Number
- NCT02741271
A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 321
- Registration Number
- NCT02741245
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)
Phase 3
Terminated
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18
- Registration Number
- NCT02668822
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)
Phase 3
Terminated
- Conditions
- Moderate to Severe Primary Dysmenorrhea
- Interventions
- Drug: Placebo vaginal ring
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 25
- Registration Number
- NCT02668783